Abstract: Objective To explore the effect and safety of anlotinib combined with chemotherapy in the treatment of patients with advanced breast cancer. Methods A retrospective analysis was performed in clinical outcomes of 10 patients with advanced breast cancer receiving anlotinib combined with chemotherapy in our hospital from July 2018 to February 2019. Results After followed up for 10 months,partial remission of anlotinib treatment was achieved in 1 case,stable disease in 3 cases,disease progression in 6 cases.The median time to treatment failure (mTTF) was 1.9 months (95% CI:1.3-2.6),and the median overall survival (mOS) was 5.4 months (95% CI:2.0-8.8).The objective response rate (ORR) was 10.0%,and the disease control rate (DCR) was 40.0%.The common adverse events were manageable such as hypertension,hand-foot syndrome,fatigue,anorexia,nausea,aspartate transaminase (AST) elevation,alanine transaminase (ALT) elevation,hypertriglyceridemia,pain.The incidence of grade 3/4 adverse reactions was 30%,included fatigue,leukopenia,and neutropenia.No drug-related death occurred. Conclusion Anlotinib shows certain effect on advanced breast cancer with manageable toxicity.